Detail akcie Atea Pharma Rg online

Business Summary: Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. The Company has built a proprietary nucleos(t)ide prodrug platform to develop product candidates to treat single-stranded ribonucleic acid (ssRNA) viruses, which are a prevalent cause of serious viral diseases. The Company’s lead program and focus is on the development of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an investigational, potent, small-molecule inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A), an essential protein for HCV replication. Bemnifosbuvir is an investigational, orally administered guanosine nucleotide double prodrug which targets the HCV non-structural protein 5B (NS5B) RNA-dependent RNA polymerase and inhibits HCV replication.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Atea Pharmaceuticals Inc revenues was not reported. Net loss decreased 16% to $113.5M. Lower net loss reflects COVID-19 external costs decrease of 98% to $1.3M (expense), Stock-based Compensation Expense decrease of 59% to $8M (expense), Research and development expense decrease of 55% to $8.1M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.60 to -$1.38.